Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06335849 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Safety and Immunogenicity Trial of the Recombinant Zoster Vaccine （CHO Cell）, LYB004 in Adults Aged 50 to 70 Years

StatusActive, Not Recruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated March 13, 2025 (before its estimated September 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

  1. Primary completion date: Feb 2025 to Sep 30, 2025
    • Trial status: Recruiting to Active, Not Recruiting
    • Study completion date: May 2025 to Sep 30, 2025
    • Site details revised
    v4
  2. Site contact updatedv3
  3. Trial status: Not Yet Recruiting to Recruiting
    • Start date changed from estimate of Apr 2024 to Mar 27, 2024
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase 1 study in Australia will evaluate the safety and immunogenicity of the Recombinant Zoster Vaccine (CHO Cell), LYB004 in Adults Aged 50 to 70 Years.
Trial Details
NCT Number NCT06335849
Lead Sponsor Guangzhou Patronus Biotech Co., Ltd.
Collaborators: Yantai Patronus Biotech Co., Ltd.
Conditions
(from sponsor)		 Herpes Zoster
Related terms Chickenpox, Herpes Zoster
Enrollment 48 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov